Correction of hemodynamics of the pelvic organs in patients with uterine myoma

1982 ◽  
Vol 63 (2) ◽  
pp. 43-45
Author(s):  
B. G. Tebelev
Keyword(s):  
Drug Treatment ◽  
Tumor Growth ◽  
Vascular Tone ◽  
Clinical Course ◽  
Uterine Myoma ◽  
Pelvic Organs

116 patients with uterine myoma before and 69 after hormonal-drug treatment were examined by the method of rheopelveography. Changes in hemodynamics and vascular tone of the pelvic organs were revealed, depending on the leading symptoms of the disease (pain, tumor growth, hypermenstrual syndrome). Taking into account rheographic indices made it possible to differentially prescribe antispasmodics and oxytotic drugs. Differentiated treatment helped improve the clinical course of the disease and normalize the hemodynamics of the pelvic organs.

Why is a new journal dedicated to vascular biology required?

2018 ◽  
Author(s):  
Paolo Madeddu
Keyword(s):  
Myocardial Ischemia ◽  
Tumor Growth ◽  
Vascular Tone ◽  
50Th Anniversary ◽  
Vascular Biology ◽  
Active Process ◽  
Master Regulators ◽  
Relaxing Factor ◽  
Tissue Healing ◽  
Endothelium Derived Relaxing Factor

The year 2018 marked the 110th anniversary of Goldmann’s discovery that vascularization is an active process in tissues1 and the 50th anniversary of the concomitant reports from Greenblatt and Shubik2 and Ehrmann and Knoth3 that soluble morphogenic factors are required for cancer angiogenesis. Many other radically transformative paradigms have been introduced in the last decades. To name a few, the molecular search for the identity of master regulators of vascular tone led to the discovery of the Endothelium-Derived Relaxing Factor (EDRF; i.e., NO4), while clinically inspired investigations led to the recognition of the pathophysiological relevance of neoangiogenesis in cancer and tissue healing. This brought about the proposal of blocking angiogenesis to halt tumor growth and stimulating angiogenesis to treat myocardial ischemia and heart failure5-7.

SPECIFICITY OF THE CLINICAL COURSE OF THE INITIAL STAGES OF HYPERTENSION IN ARID ZONES OF UZBEKISTAN AND NON-DRUG APPROACHES TO TREATMENT

2020 ◽  
Author(s):  
U.R. Narzulaeva ◽  
G.U. Samieva ◽  
M.Sh. Ismatova
Keyword(s):  
At Risk ◽  
Drug Treatment ◽  
Healthy Lifestyle ◽  
Clinical Course ◽  
Arid Zones ◽  
Etiological Factors ◽  
Renin Angiotensin ◽  
Early Stages ◽  
Hot Climate ◽  
Patients At Risk

The article describes the etiological factors, the course and risks of the development of hypertension in the early stages in a hot climate. The data on the pathogenesis of hypertension and the effects of pathogenetic variants of the sympatho-adrenal and renin-angiotensin systems are summarized. Non-drug treatment is proposed by observing a healthy lifestyle in patients at risk.

scholarly journals Acromegaly and pregnancy: a prospective study

2014 ◽  
Vol 170 (2) ◽  
pp. 301-310 ◽  
Author(s):  
Monike Dias ◽  
Cesar Boguszewski ◽  
Monica Gadelha ◽  
Leandro Kasuki ◽  
Nina Musolino ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Drug Treatment ◽  
Tumor Growth ◽  
Magnetic Resonance Image ◽  
Exclusion Criterion ◽  
Prospective Data ◽  
Multicentric Study ◽  
Previous Diagnosis ◽  
Active Acromegaly ◽  
A Prospective Study

Context and objectiveThe interaction between pregnancy and acromegaly has been studied only retrospectively. We used prospective data to assess those interactions.DesignProspective, interventional, multicentric study.PatientsTen pregnancies in eight acromegalic patients were included according to the following criteria: previous diagnosis of acromegaly; and active acromegaly before pregnancy. Sellar magnetic resonance image (MRI), GH, and IGF1 measurements were carried out before pregnancy. The exclusion criterion was radiotherapy.InterventionWithdrawal of pharmacological treatment (octreotide and/or cabergoline and/or pegvisomant) following pregnancy diagnosis.Main outcome measuresClinical/biochemical evaluations throughout pregnancy/puerperium and sellar MRI after delivery; and GH and IGF1 measurements before pregnancy. GH was measured by an interference-free IFMA assay during pregnancy and IGF1 by measured by Immulite 2000 assay in patients and 64 control pregnancies.ResultsNo tumor growth was observed. Nine deliveries were at term and one at 35 weeks (preeclampsia). All newborns were healthy. Mean IGF1 levels before and during pregnancy were similar, but increased significantly during puerperium. As IGF1 in controls increased after midgestation, the prevalence of controlled IGF1 rose significantly from 2/10 (<20 weeks) to 9/10 (>30 weeks). Diabetes mellitus and hypertension/preeclampsia developed in one patient in each group; both complications were nonsignificantly (P=0.06) associated with IGF1 >1.3 ULN before pregnancy.ConclusionsAcromegaly control usually improved and tumor growth was not stimulated during pregnancy in spite of withdrawal of drug treatment. Drug treatment can be discontinued in most patients. Uncontrolled disease before pregnancy may pose a higher risk for diabetes and hypertension.

scholarly journals Multiple faces of bronchial asthma

2010 ◽  
Vol 7 (1) ◽  
pp. 40-52
Author(s):  
G B Fedoseev ◽  
V I T rofimov ◽  
G B Fedoseev ◽  
V I Trofimov
Keyword(s):  
Drug Treatment ◽  
Effective Treatment ◽  
Bronchial Asthma ◽  
Clinical Course ◽  
Treatment Plan ◽  
Allergic Diseases ◽  
The Other ◽  
Infectious Agents ◽  
Individual Features

The analysis of publications and results of original investigations concerning the pathogenesis and clinical course of bronchial asthma is performed. B ronchial asthma is a markedly heterogeneous disease, the heterogeneity is due to the differences in severity cause, phases, clinical pathogenetic variants, associations with the other allergic diseases, COP D, diseases of other organs, influence of different allergens and infectious agents. T hus, the effective treatment plan should be based also on attention to individual features of the patient and include both drugs and methods of non-drug treatment.

SPECIFICITY OF THE CLINICAL COURSE OF THE INITIAL STAGES OF HYPERTENSION IN ARID ZONES OF UZBEKISTAN AND NON-DRUG APPROACHES TO TREATMENT

2020 ◽  
Author(s):  
U.R. Narzulaeva ◽  
G.U. Samieva ◽  
M.Sh. Ismatova
Keyword(s):  
At Risk ◽  
Drug Treatment ◽  
Healthy Lifestyle ◽  
Clinical Course ◽  
Arid Zones ◽  
Etiological Factors ◽  
Renin Angiotensin ◽  
Early Stages ◽  
Hot Climate ◽  
Patients At Risk

The article describes the etiological factors, the course and risks of the development of hypertension in the early stages in a hot climate. The data on the pathogenesis of hypertension and the effects of pathogenetic variants of the sympatho-adrenal and renin-angiotensin systems are summarized. Non-drug treatment is proposed by observing a healthy lifestyle in patients at risk.

Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease

1989 ◽  
Vol 120 (6) ◽  
pp. 689-701 ◽  
Author(s):  
H. Schleusener ◽  
J. Schwander ◽  
C. Fischer ◽  
R. Holle ◽  
G. Holl ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Multicentre Study ◽  
Drug Treatment ◽  
Clinical Course ◽  
Antithyroid Drug ◽  
Graves Disease ◽  
Trh Test ◽  
Prospective Multicentre Study ◽  
Antithyroid Drug Therapy ◽  
Antithyroid Drug Treatment

Abstract. Graves' disease is an autoimmune disease characterized by a course of remission and relapse. Since the introduction of antithyroid drug treatment, various parameters have been tested for their ability to predict the clinical course of a patient with Graves' disease after drug withdrawal. Nearly all these studies were prospective and often yielded conflicting results. In a prospective multicentre study with a total of 451 patients, we investigated the significance of a variety of routine laboratory and clinical parameters for predicting a patient's clinical course. Patients who had positive TSH receptor antibodies activity at the end of therapy showed a significantly higher relapse rate than those without (P< 0.001). However, the individual clinical course cannot be predicted exactly (sensitivity 0.49, specificity 0.73, N = 391). The measurement of microsomal (P=0.99, sensitivity 0.37, specificity 0.63, N = 275) or thyroglobulin antibodies (P= 0.76, sensitivity 0.18, specificity 0.84, N = 304) at the end of antithyroid drug therapy did not show a statistically significant difference in the antibody titre between the patients of the relapse and those of the remission group. Additionally, HLA-DR typing (HLA-DR3: P=0.37, sensitivity 0.36, specificity 0.58, N = 253) was proven to be unsuitable for predicting a patient's clinical course. Patients with abnormal suppression or an abnormal TRH test at the end of antithyroid drug therapy relapse significantly more often (P< 0.001) than patients with normal suppression or normal TRH test. Patients with a large goitre also have a significantly (P< 0.001) higher relapse rate than those with only a small enlargement. The sensitivity and specificity values of all these parameters, however, were too low to be useful for daily clinical decisions in the treatment of an individual patient. This is also true for the combinations of different parameters. Though the highest sensitivity value (0.94) was found for a combination of the suppression and the TRH test at the end of therapy, the very low specificity value (0.13) for this combination reduced its clinical usefulness.

scholarly journals A Couple with Different Symptoms after Simultaneously 2019-nCoV Infected

2020 ◽  
Author(s):  
Ying Zhang ◽  
Huaping Tang ◽  
Jing Li ◽  
Feng Zhang ◽  
Jianyou Chen ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Drug Treatment ◽  
Human Health ◽  
Respiratory System ◽  
Treatment Process ◽  
Clinical Course ◽  
Diagnosis And Treatment ◽  
Igg Antibody ◽  
Case Presentation ◽  
Course Characteristics

Abstract Background 2019-nCoV has posed a significant threat to human health since the epidemic began. So far, there is no definite safe and effective drug treatment. Proper management can help prevent mild patients from becoming severe. We report a couple with different symptoms after simultaneously infected by the same source of 2019-nCoV and analyze the changes in the diagnosis and treatment process. Case presentation We report a couple with different symptoms after simultaneously infected by the same source of 2019-nCoV in Shandong, China，describe their clinical course，characteristics and detection results in detail, and analyze the changes in the diagnosis and treatment process. The wife was mainly affected by respiratory system and had ever experienced high fever for several days. The husband's condition is lighter than his wife，mainly manifested as digestive tract symptoms，but it took longer than his wife for the nucleic acid of nasopharynx swab for 2019-nCoV to turn negative. Conclusions In the course of the disease both of the couple had hypokalemia which was easy to be corrected. CRP and ESR were consistent with the changes of the disease during the 2019-nCoV infection, which were good indicators to reflect the severity and development of the disease. Two months after discharge, both of them showed negative IgM antibody and positive IgG antibody.

Do HLA-DR-typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment?

1987 ◽  
Vol 116 (1_Suppl) ◽  
pp. S318-S324 ◽  
Author(s):  
H. Schleusener ◽  
J. Schwander ◽  
G. Holl ◽  
K. Badenhoop ◽  
J. Hensen ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Clinical Course ◽  
Antithyroid Drug ◽  
Tsh Receptor ◽  
Hla Dr ◽  
Number Of Patients ◽  
Antithyroid Drug Treatment ◽  
The Many ◽  
Receptor Antibodies ◽  
Tsh Receptor Antibodies

Abstract. In patients with Graves' hyperthyroidism, the relapse rate after antithyroid drug treatment is in the range of about 30–70%. Different attempts have been made to obtain criteria for the prediction of the clinical outcome after drug therapy, especially HLA-DR typing and measurement of TSH receptor antibodies. So far, very conflicting results have been reported. This is not surprising in view of the many genetically controlled and environmental factors that play a role in the pathogenesis of this disease. Moreover, most reports are based on retrospective studies with a relatively small number of patients. Our own data, obtained in a prospective multicenter study, yield strong evidence against the relevance of HLA-DR3 typing (n = 187, sensitivity = 0.38, specificity = 0.67) or measurement of TSH receptor antibodies at the end of therapy (n = 269, sensitivity = 0.49, specificity = 0.72) for the prediction of the clinical course after drug treatment.

Aggressive course of a rare type of urethral cancer in women

2020 ◽  
Vol 10 (2) ◽  
pp. 181-186
Author(s):  
Olga S. Streltsova ◽  
Katerina E. Yunusova ◽  
Valentin N. Krupin ◽  
Vasiliy V. Vlasov ◽  
Anton S. Kuyarov
Keyword(s):  
Clear Cell ◽  
Clinical Course ◽  
Malignant Tumors ◽  
Cancer Surveillance ◽  
Clear Cell Adenocarcinoma ◽  
Rare Form ◽  
Rare Type ◽  
Pelvic Organs ◽  
Proximal Urethra ◽  
Urethral Diseases

The article provides a clinical case of urethral cancer in women. Primary urethral carcinomas are rare, less than 1% of all malignant tumors. According to the Rarecare Cancer Surveillance Agency for Europe (RARECARE), urethral cancer in women is 0.6 and 1.6 in men per 1 million people per year. A 56-year-old patient with histologically verified clear cell adenocarcinoma of the proximal urethra was monitored for 18 months. An aggressive course of the tumor process has been shown, which led to the need to perform anterior exenteration of the pelvic organs. The histogenesis of primary clear cell urethral adenocarcinoma has not been definitively determined. The atypical external localization in the described case suggests the periurethral origin of this cancerous tumor from the Skenes glands. The demonstration of a rare form of urethral cancer, clear cell adenocarcinoma, contributes to the accumulation of knowledge about its histopathology and clinical course, as well as increasing cancer alertness in the treatment of urethral diseases in doctors of any specialty.

Sign in / Sign up

Export Citation Format

Share Document